SlideShare a Scribd company logo
1 of 20
Download to read offline
HATCH-WAXMANACT
BY
V.DEEPIKA
M.PHARM IYR
(PHARMACEUTICS)
CONTENT
 Introduction
 Objectives of the act
 Provisions of the act
 Orange book
 Types of patent certification
 Para IV- patent challenge
 Incentives and protection
 Para IV deadline
 Delay in generic entry
INTRODUCTION
 It is Also known as “THE DRUG PRICE COMPETITION
AND PATENT TERM RESTORATION ACT”
 Enacted in 1984 .
 Amended the patent laws
 Before 1962- new drug approval based on safety alone
 In 1962-proof of efficacy made compulsory for marketing
approval of a new drug (Kefauver-Harris Amendments)
 There was no provision for patent term extension prior to
enactment of the Hatch Waxman Act, to make up for the time
lost out of the total patent term during the marketing approval
process
CONT…
 Generic companies required to submit their own comprehensive
NDA
Costly
Time consuming
 If drug was covered by patent ,Testing could not begin until
patent expired.
 To overcome the above problems an act was needed to promote
generic companies
OBJECTIVES
 Reducing the cost associated with the approval of a generic
drug
 Allowing Early-Experimental-Use
 Compensating the branded drugs manufacturers for the
time lost from the patent term because of the regulatory
approval formality
 Motivating the generic drug manufacturers
PROVISIONS
 Creation of section 505(j)
 Section 505(j) established the ANDA approval process
 The timing of an ANDA approval depends in part on patent
protections for the innovator drug
 NDA must include any patent that claims the "drug" or a
"method of using [the] drug" for which a claim of patent
infringement could reasonably be asserted
 On approval of NDA, FDA publishes patent information for
drug in Orange Book (“Approved Drug Products with
Therapeutic Equivalence Evaluations”)
ORANGE BOOK
 FDA publishes patent information on approved drug products in
the Orange Book
 An NDA applicant must submit the following information for
each patent:
Patent no and date on which the patent will expire
Type of patent, i.e. drug, drug product, or method of use
Name of patent owner
The name of an agent of the patent owner or applicant
 Brand drugs listed for generics to compare with their proposed
products
TYPES OF
PATENT
CERTIFICATION
 When an applicant submits an ANDA to the FDA, the applicant
must certify one of four things under section 505(j)(2)(A)(vii):
That the required patent information relating to such patent has
not been filed (Para I) ;
That such patent has expired (Para II) ;
That the patent will expire on a particular date (Para III);
That such patent is invalid or will not be infringed by the drug,
for which approval is being sought (Para IV – Patent
Challenge)
PARAIV- PATENT
CHALLENGE
GENERIC- para IV filing
GENERIC- provide notice to brand within 20 days of
acceptance
BRAND- must bring lawsuit within 45 days
GENERIC- if sued, automatic 30 month stay granted to
BRAND
CONT…
INCENTIVES
AND
PROTECTION
 180 day market exclusivity:
 First applicant to submit a substantially complete ANDA (first
to file)
 30month stay of FDA approval:
 If patent owner or NDA holder sues the ANDA applicant for
patent infringement within 45 days of receiving notice of the
Paragraph IV certification
 Runs from date of notification or expiration of NCE exclusivity
 May be lengthened or shortened by the court
PARA- IV
DEADLINES
NOTIFICATION LETTER : 20 DAYS
 Upon ANDA acceptance for filing, the applicant must notify the
NDA holder and patent owner of the ANDA within 20 days.
The notice must include a detailed statement of the factual and
legal basis of the opinion of the applicant that the patent is
invalid or will not be infringed
LAWSUIT: 45 DAYS
 Upon notification, the NDA holder and patent owners have 45
days in which to initiate an action for patent infringement. If
such an action is brought within 45 days, the ANDA is subject
to a 30-month stay of FDA approval beginning on the date the
notification letter was received
BENEFITSFOR
BRANDED
MANUFACTURER
 Orange Book provides public notice of patents
 Allows for resolution of patent disputes prior to generic entry
 30-month stay of FDA approval of generic drugs
 Patent Term Restoration
 Allows for Several Market Exclusivities:
 Data Exclusivity
 5 years for New Chemical Entity (NCE) Drug
 3 years for non-NCE Drug
 Orphan Drug (7 years)
 Pediatric (PEDS) (6 months)
BENEFICTSFOR
GENERIC
MANUFACTURES
 180-day market exclusivity for first successful challenger to
Orange Book patent
 Allows generics to challenge Orange Book patents without risk
of damages
 “Safe Harbor” rule allows generics to perform bioequivalence
and other testing relating to regulatory approval without risk of
patent infringement
DELAY IN
GENERIC ENTRY
 Reverse payment agreements
 Sham litigations
 Sham citizens petitions
 Walker process
 Product hopping
REVERSE
PAYMENT
AGREEMENTS
 Both parties decide it is in their mutual best interests to settle
via a significant payment from the patent owner/branded to
the generic to keep the generic drug off the market
 The generic may make more money than by rushing to
market the drug
 The branded may also make more money by paying the
generic to defer marketing the drug for a certain period of time
SHAM
LITIGATIONS
 Brand sues generic for patent infringement
 Court finds for generic, often on SJ, and holds patent invalid or
unenforceable
 Hatch-Waxman 30-month stay allows brand to win even if they
lose
 Plaintiffs must prove brand’s infringement suit is objectively
and subjectively baseless
SHAM CITIZEN
PETITIONS
 Companies can petition FDA to not approve an ANDA
Should be based on safety or formulation concerns
 Citizen’s Petitions delay approval of ANDAs
Ripe for abuse, and often abused
 Delay itself is the goal
 Same standard as Sham Litigation
WALKER
PROCESS
 Antitrust violation premised on fraud on the PTO
 Patent applicants have a duty of candor to PTO because
applications are ex part
 Elements track fraud claims
 Often coupled with Sham Litigation and other theories
PRODUCT
HOPPING
 Delay sometimes allows brands to introduce new versions of
the product
 Changes are often minimal but can defeat generic competition
 Brands actively convert the market
– Free samples
– Pulling the “old” product from the market

More Related Content

What's hot

DRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTS
DRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTSDRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTS
DRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTSNaila Kanwal
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)Dr. Jigar Vyas
 
Hatch waxman act & amendments ppt
Hatch waxman act & amendments  pptHatch waxman act & amendments  ppt
Hatch waxman act & amendments pptAlexa Jacob
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USAsandeep bansal
 
CMC , POST APPROVAL CHANGES.pptx
CMC , POST APPROVAL CHANGES.pptxCMC , POST APPROVAL CHANGES.pptx
CMC , POST APPROVAL CHANGES.pptxSakshiSonawane6
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japanManish kumar
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)Swapnil Fernandes
 
Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.Naila Kanwal
 
CTD and ECTD Document
CTD and ECTD Document CTD and ECTD Document
CTD and ECTD Document Nirmal Maurya
 
Hatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika DeyHatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika DeyKushal Saha
 
ANDA APPROVAL PROCESS.pptx
ANDA APPROVAL PROCESS.pptxANDA APPROVAL PROCESS.pptx
ANDA APPROVAL PROCESS.pptxPawanDhamala1
 
Anda review process
Anda review processAnda review process
Anda review processbinnz
 

What's hot (20)

eCTD
eCTDeCTD
eCTD
 
DRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTS
DRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTSDRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTS
DRUG MASTER FILE AND GLOBAL REGULATORY REQUIREMENTS
 
Hatch waxman act
Hatch waxman actHatch waxman act
Hatch waxman act
 
Naresh... anda ppt
Naresh... anda pptNaresh... anda ppt
Naresh... anda ppt
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)
 
Hatch waxman act & amendments ppt
Hatch waxman act & amendments  pptHatch waxman act & amendments  ppt
Hatch waxman act & amendments ppt
 
hatch-waxman act@amendments
hatch-waxman act@amendmentshatch-waxman act@amendments
hatch-waxman act@amendments
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USA
 
CMC , POST APPROVAL CHANGES.pptx
CMC , POST APPROVAL CHANGES.pptxCMC , POST APPROVAL CHANGES.pptx
CMC , POST APPROVAL CHANGES.pptx
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japan
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.Dossier Management and Regulatory Affairs.
Dossier Management and Regulatory Affairs.
 
CTD and ECTD Document
CTD and ECTD Document CTD and ECTD Document
CTD and ECTD Document
 
Drug master file
Drug master fileDrug master file
Drug master file
 
Hatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika DeyHatch Waxman Act by Anamika Dey
Hatch Waxman Act by Anamika Dey
 
ANDA APPROVAL PROCESS.pptx
ANDA APPROVAL PROCESS.pptxANDA APPROVAL PROCESS.pptx
ANDA APPROVAL PROCESS.pptx
 
Anda review process
Anda review processAnda review process
Anda review process
 
ANDA filing
ANDA filingANDA filing
ANDA filing
 

Similar to Hatch waxman act

Hatch waxman act my ppt
Hatch waxman act my pptHatch waxman act my ppt
Hatch waxman act my pptMansiGangwar5
 
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.Aakashdeep Raval
 
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHAREHATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHAREvamshipradeep
 
Drug Regulatory Affairs, PPT by Sirisha Spandana rao
Drug Regulatory Affairs, PPT by Sirisha Spandana raoDrug Regulatory Affairs, PPT by Sirisha Spandana rao
Drug Regulatory Affairs, PPT by Sirisha Spandana raoGandrapuSpandanarao
 
Hatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptxHatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptxSumeet Dhakane
 
Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...Mohit Kumar
 
Presentation on ANDA litigation
Presentation on ANDA litigationPresentation on ANDA litigation
Presentation on ANDA litigationVikram Jeet Singh
 
Hatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceHatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceMoremrunal
 
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNilesh Gawade
 
global submission of ANDA .pptx
global submission of ANDA .pptxglobal submission of ANDA .pptx
global submission of ANDA .pptxAbdulNaim14
 
ANDA Filling Process
ANDA Filling ProcessANDA Filling Process
ANDA Filling ProcessVipin Adlak
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product developmentSachin G
 

Similar to Hatch waxman act (20)

Hatch waxman act my ppt
Hatch waxman act my pptHatch waxman act my ppt
Hatch waxman act my ppt
 
WorkSample#2PARA -IV FILINGS
WorkSample#2PARA -IV FILINGSWorkSample#2PARA -IV FILINGS
WorkSample#2PARA -IV FILINGS
 
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
 
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHAREHATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
HATCH-WAXMAN ACT & AMENDMENTS SLIDESHARE
 
Drug Regulatory Affairs, PPT by Sirisha Spandana rao
Drug Regulatory Affairs, PPT by Sirisha Spandana raoDrug Regulatory Affairs, PPT by Sirisha Spandana rao
Drug Regulatory Affairs, PPT by Sirisha Spandana rao
 
Hatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptxHatch-Waxmann Act.pptx
Hatch-Waxmann Act.pptx
 
Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...
 
Hatch Waxman Act
Hatch Waxman Act  Hatch Waxman Act
Hatch Waxman Act
 
Presentation on ANDA litigation
Presentation on ANDA litigationPresentation on ANDA litigation
Presentation on ANDA litigation
 
The hatch waxman act
The hatch waxman actThe hatch waxman act
The hatch waxman act
 
Hatch waxman act
Hatch waxman actHatch waxman act
Hatch waxman act
 
HATCH -WAXMAN ACT
HATCH -WAXMAN ACTHATCH -WAXMAN ACT
HATCH -WAXMAN ACT
 
guide.pdf
guide.pdfguide.pdf
guide.pdf
 
ANDA.pptx
ANDA.pptxANDA.pptx
ANDA.pptx
 
Hatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillanceHatch waxman act and post marketing survillance
Hatch waxman act and post marketing survillance
 
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNDA and ANDA regulatory approval process
NDA and ANDA regulatory approval process
 
global submission of ANDA .pptx
global submission of ANDA .pptxglobal submission of ANDA .pptx
global submission of ANDA .pptx
 
ANDA Filling Process
ANDA Filling ProcessANDA Filling Process
ANDA Filling Process
 
Anda filing
Anda filingAnda filing
Anda filing
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 

Recently uploaded

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 

Recently uploaded (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 

Hatch waxman act

  • 2. CONTENT  Introduction  Objectives of the act  Provisions of the act  Orange book  Types of patent certification  Para IV- patent challenge  Incentives and protection  Para IV deadline  Delay in generic entry
  • 3. INTRODUCTION  It is Also known as “THE DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT”  Enacted in 1984 .  Amended the patent laws  Before 1962- new drug approval based on safety alone  In 1962-proof of efficacy made compulsory for marketing approval of a new drug (Kefauver-Harris Amendments)  There was no provision for patent term extension prior to enactment of the Hatch Waxman Act, to make up for the time lost out of the total patent term during the marketing approval process
  • 4. CONT…  Generic companies required to submit their own comprehensive NDA Costly Time consuming  If drug was covered by patent ,Testing could not begin until patent expired.  To overcome the above problems an act was needed to promote generic companies
  • 5. OBJECTIVES  Reducing the cost associated with the approval of a generic drug  Allowing Early-Experimental-Use  Compensating the branded drugs manufacturers for the time lost from the patent term because of the regulatory approval formality  Motivating the generic drug manufacturers
  • 6. PROVISIONS  Creation of section 505(j)  Section 505(j) established the ANDA approval process  The timing of an ANDA approval depends in part on patent protections for the innovator drug  NDA must include any patent that claims the "drug" or a "method of using [the] drug" for which a claim of patent infringement could reasonably be asserted  On approval of NDA, FDA publishes patent information for drug in Orange Book (“Approved Drug Products with Therapeutic Equivalence Evaluations”)
  • 7. ORANGE BOOK  FDA publishes patent information on approved drug products in the Orange Book  An NDA applicant must submit the following information for each patent: Patent no and date on which the patent will expire Type of patent, i.e. drug, drug product, or method of use Name of patent owner The name of an agent of the patent owner or applicant  Brand drugs listed for generics to compare with their proposed products
  • 8. TYPES OF PATENT CERTIFICATION  When an applicant submits an ANDA to the FDA, the applicant must certify one of four things under section 505(j)(2)(A)(vii): That the required patent information relating to such patent has not been filed (Para I) ; That such patent has expired (Para II) ; That the patent will expire on a particular date (Para III); That such patent is invalid or will not be infringed by the drug, for which approval is being sought (Para IV – Patent Challenge)
  • 9. PARAIV- PATENT CHALLENGE GENERIC- para IV filing GENERIC- provide notice to brand within 20 days of acceptance BRAND- must bring lawsuit within 45 days GENERIC- if sued, automatic 30 month stay granted to BRAND
  • 11. INCENTIVES AND PROTECTION  180 day market exclusivity:  First applicant to submit a substantially complete ANDA (first to file)  30month stay of FDA approval:  If patent owner or NDA holder sues the ANDA applicant for patent infringement within 45 days of receiving notice of the Paragraph IV certification  Runs from date of notification or expiration of NCE exclusivity  May be lengthened or shortened by the court
  • 12. PARA- IV DEADLINES NOTIFICATION LETTER : 20 DAYS  Upon ANDA acceptance for filing, the applicant must notify the NDA holder and patent owner of the ANDA within 20 days. The notice must include a detailed statement of the factual and legal basis of the opinion of the applicant that the patent is invalid or will not be infringed LAWSUIT: 45 DAYS  Upon notification, the NDA holder and patent owners have 45 days in which to initiate an action for patent infringement. If such an action is brought within 45 days, the ANDA is subject to a 30-month stay of FDA approval beginning on the date the notification letter was received
  • 13. BENEFITSFOR BRANDED MANUFACTURER  Orange Book provides public notice of patents  Allows for resolution of patent disputes prior to generic entry  30-month stay of FDA approval of generic drugs  Patent Term Restoration  Allows for Several Market Exclusivities:  Data Exclusivity  5 years for New Chemical Entity (NCE) Drug  3 years for non-NCE Drug  Orphan Drug (7 years)  Pediatric (PEDS) (6 months)
  • 14. BENEFICTSFOR GENERIC MANUFACTURES  180-day market exclusivity for first successful challenger to Orange Book patent  Allows generics to challenge Orange Book patents without risk of damages  “Safe Harbor” rule allows generics to perform bioequivalence and other testing relating to regulatory approval without risk of patent infringement
  • 15. DELAY IN GENERIC ENTRY  Reverse payment agreements  Sham litigations  Sham citizens petitions  Walker process  Product hopping
  • 16. REVERSE PAYMENT AGREEMENTS  Both parties decide it is in their mutual best interests to settle via a significant payment from the patent owner/branded to the generic to keep the generic drug off the market  The generic may make more money than by rushing to market the drug  The branded may also make more money by paying the generic to defer marketing the drug for a certain period of time
  • 17. SHAM LITIGATIONS  Brand sues generic for patent infringement  Court finds for generic, often on SJ, and holds patent invalid or unenforceable  Hatch-Waxman 30-month stay allows brand to win even if they lose  Plaintiffs must prove brand’s infringement suit is objectively and subjectively baseless
  • 18. SHAM CITIZEN PETITIONS  Companies can petition FDA to not approve an ANDA Should be based on safety or formulation concerns  Citizen’s Petitions delay approval of ANDAs Ripe for abuse, and often abused  Delay itself is the goal  Same standard as Sham Litigation
  • 19. WALKER PROCESS  Antitrust violation premised on fraud on the PTO  Patent applicants have a duty of candor to PTO because applications are ex part  Elements track fraud claims  Often coupled with Sham Litigation and other theories
  • 20. PRODUCT HOPPING  Delay sometimes allows brands to introduce new versions of the product  Changes are often minimal but can defeat generic competition  Brands actively convert the market – Free samples – Pulling the “old” product from the market